According to EyePoint Pharmaceuticals 's latest financial reports the company's current revenue (TTM) is $46.01 M. In 2022 the company made a revenue of $41.4 M an increase over the years 2021 revenue that were of $36.93 M.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Year | Revenue | Change |
---|---|---|
2023 (TTM) | $46.01 M | 11.14% |
2022 | $41.4 M | 12.09% |
2021 | $36.93 M | 7.27% |
2020 | $34.43 M | 69.11% |
2019 | $20.36 M | |
2017 | $2.6 M | -62.06% |
2016 | $6.87 M | 297.69% |
2015 | $1.72 M | -93.85% |
2014 | $28.11 M | 1181.31% |
2013 | $2.19 M | -7.62% |
2012 | $2.37 M | -62.68% |
2011 | $6.36 M | -62.84% |
2010 | $17.12 M | 29.73% |
2009 | $13.2 M | 46.35% |
2008 | $9.02 M | 1101.2% |
2007 | $0.75 M | -63.54% |
2006 | $2.06 M | 52.08% |
2005 | $1.35 M | 213.52% |
2004 | $0.43 M | 143.31% |
2003 | $0.17 M |
Company | Revenue | Revenue differencediff. | Country |
---|---|---|---|
Nymox Pharmaceutical NYMX | N/A | N/A | Bahamas |
NRC Health
NRC | $0.14 B | 222.87% | ๐บ๐ธ USA |